Perlinganite, concentrate 1 mg/ml 10 pcs 10 pcs

Stenocardia (unstable and vasospastic), acute myocardial infarction, acute left ventricular failure, hypertensive crisis with a background of heart failure, controlled hypotension.

Indications

Angina pectoris (unstable and vasospastic), acute myocardial infarction, acute left ventricular failure, hypertensive crisis due to heart failure, controlled hypotension.

Pharmacological effect

Perlinganite has a vasodilator and antianginal effect.

Special instructions

Infusion systems made of polyethylene, polypropylene, polytetrafluoroethylene or glass should be used (but not polyvinyl chloride and polyurethane, as they adsorb the active substance and therefore may require an increase in dose).

Active ingredient

Nitroglycerine

Composition

1 ampoule with 10 ml of solution for infusion contains 10 mg of nitroglycerin in an isotonic 5% glucose solution.

Contraindications

Acute circulatory failure (shock, vascular collapse); severe hypotension (systolic blood pressure below 95 mm Hg); cardiogenic shock (with simultaneous use of drugs with a positive inotropic effect or balloon counterpulsation).

Side Effects

Headache, drowsiness, weakness, decreased blood pressure, tachycardia, nausea, vomiting.

Interaction

When used simultaneously with other vasodilators (vasodilators), antihypertensive drugs, beta-blockers, calcium channel blockers, phosphodiesterase type 5 inhibitors used to treat erectile dysfunction (for example, sildenafil), antipsychotics, tricyclic antidepressants, and ethanol, the hypotensive effect may be enhanced.

With the simultaneous use of Perlinganite with dihydroergotamine, an increase in the concentration of dihydroergotamine in the blood may be observed, which leads to an increase in its hypotensive effect.

With the simultaneous use of heparin and Perlinganite, the effect of heparin may be weakened. Under the control of blood clotting parameters, the appropriate dose of heparin is selected. After stopping the infusion of Perlinganite, a significant decrease in blood clotting is possible, which may require a reduction in the dose of heparin.

With the simultaneous use of Perlinganite solution and tissue plasminogen activator, a decrease in the concentration in the blood and a decrease in the effectiveness of the latter have been described.

Overdose

Symptoms: a sharp decrease in blood pressure, a reflex increase in heart rate, a feeling of general weakness, dizziness and lethargy, as well as headache, redness of the skin of the face or upper half of the body, nausea, vomiting and diarrhea. When using the drug in high doses (more than 20 mg/kg body weight), methemoglobinemia, cyanosis, shortness of breath and tachypnea may develop; increased intracranial pressure with cerebral symptoms is possible.

Treatment: it is necessary to monitor the function of vital organs.

In case of severe arterial hypotension and/or shock, the volume of circulating blood should be increased; in exceptional cases, an infusion of norepinephrine (norepinephrine) and/or dopamine can be given. The use of epinephrine (adrenaline) and related substances is contraindicated.

For methemoglobinemia, depending on the severity, the following antidotes are recommended: ascorbic acid (1 g orally or intravenously in the form of sodium salt); methylene blue (up to 50 mg of 1% solution of methylene blue intravenously); toluidine blue (initial dose 2-4 mg/kg body weight intravenously; if necessary, repeated repetitions at hourly intervals of 2 mg/kg body weight). Oxygen therapy, hemodialysis, and blood transfusion are indicated.

Storage conditions

At room temperature no higher than 25 °C

Shelf life

5 years

Manufacturer

EVER Pharma Jena GmbH, Germany